Effects of Providing Information through an Enhanced Collaborative Model Care Fee and Anticancer Agent Use Follow-up Sheet on Patient Follow-up by Community Pharmacists

In April 2023, we revised the forms required to calculate an enhanced collaborative model care fee. The anticancer agent follow-up sheet used by community pharmacists was also revised in September 2023 and was designed to automatically highlight potential adverse events that would require monitoring once an anticancer agent was selected. We investigated the number of cases for which an enhanced collaborative model care fee was calculated and the number of cases for which information was provided by community pharmacists over three periods: Period 1 from October 1, 2022 to March 31, 2023; Period 2 from April 1, 2023 to September 30, 2023; and Period 3 from October 1, 2023 to March 31, 2024. The number of cases with calculated enhanced collaborative model care fee significantly increased from 234 cases in Period 1 to 969 cases in Period 2 and 1087 cases in Period 3. Based on the information provided by community pharmacists, the number of follow-up patients receiving injectable anticancer agents increased significantly in Period 3 compared with Periods 1 and 2, with four cases identified in Period 1, 11 in Period 2, and 34 in Period 3. These results suggest that providing community pharmacists with specific information through enhanced collaborative model care fee and using the anticancer agent follow-up sheet by community pharmacists helped improve follow-up assessments on various cancer chemotherapy regimens.